JP2024542738A5 - - Google Patents

Info

Publication number
JP2024542738A5
JP2024542738A5 JP2024532733A JP2024532733A JP2024542738A5 JP 2024542738 A5 JP2024542738 A5 JP 2024542738A5 JP 2024532733 A JP2024532733 A JP 2024532733A JP 2024532733 A JP2024532733 A JP 2024532733A JP 2024542738 A5 JP2024542738 A5 JP 2024542738A5
Authority
JP
Japan
Application number
JP2024532733A
Other languages
Japanese (ja)
Other versions
JP2024542738A (ja
JPWO2023102488A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080764 external-priority patent/WO2023102488A2/en
Publication of JP2024542738A publication Critical patent/JP2024542738A/ja
Publication of JPWO2023102488A5 publication Critical patent/JPWO2023102488A5/ja
Publication of JP2024542738A5 publication Critical patent/JP2024542738A5/ja
Pending legal-status Critical Current

Links

JP2024532733A 2021-12-01 2022-12-01 疼痛の治療のための組成物及び方法 Pending JP2024542738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284957P 2021-12-01 2021-12-01
US63/284,957 2021-12-01
PCT/US2022/080764 WO2023102488A2 (en) 2021-12-01 2022-12-01 Compositions and methods for treatment of pain

Publications (3)

Publication Number Publication Date
JP2024542738A JP2024542738A (ja) 2024-11-15
JPWO2023102488A5 JPWO2023102488A5 (https=) 2025-12-08
JP2024542738A5 true JP2024542738A5 (https=) 2025-12-08

Family

ID=86613161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532733A Pending JP2024542738A (ja) 2021-12-01 2022-12-01 疼痛の治療のための組成物及び方法

Country Status (9)

Country Link
US (1) US20250109402A1 (https=)
EP (1) EP4441228A2 (https=)
JP (1) JP2024542738A (https=)
KR (1) KR20240131349A (https=)
CN (1) CN118632929A (https=)
AU (1) AU2022403005A1 (https=)
CA (1) CA3240948A1 (https=)
MX (1) MX2024006649A (https=)
WO (1) WO2023102488A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025108284A1 (en) * 2023-11-20 2025-05-30 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of sodium voltage-gated channel alpha subunit 9 (scn9a)
WO2025140551A1 (en) * 2023-12-29 2025-07-03 Neuro3 Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain

Similar Documents

Publication Publication Date Title
JP2024511473A5 (https=)
CL2025003892A1 (es) Monitoreo de una condición de un medio de cribado
JP2024542738A5 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BY23990C1 (https=)
BY13172U (https=)
CN307048218S (https=)
CN307047769S (https=)
CN307047541S (https=)
CN307046599S (https=)
CN307046471S (https=)
CN307046015S (https=)
BY13137U (https=)
CN307045575S (https=)
CN307045448S (https=)
CN307044698S (https=)
CN307044189S (https=)
CN307048993S (https=)
BY13135U (https=)
BY13162U (https=)
BY23963C1 (https=)